When should AML testing happen, and which tests are most important? Dr. David Sallman explains why comprehensive testing should begin at diagnosis, which key tests patients should ask about, and how identifying specific genetic changes can guide treatment decisions and personalize care.
Dr. David Sallman is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center where he specializes in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Learn more about Dr. Sallman.
Related Resources
Transcript
Katherine Banwell:
How soon after a diagnosis should testing be done?
Dr. David Sallman:
So, basically, it should be done hand-in-hand. So, essentially, many patients with AML, right, already have peripheral blood counts that could look consistent with that. So, essentially, we send everything from our very first diagnostic sample. There could be some patients that have low blood counts, and maybe it’s not clear that they have circulating blasts. And so, some of those patients could eventually need some additional testing. But really, any diagnostic sample should have it all done from the very beginning.
Usually, there’s enough sample drawn that tests can be added on because, especially for things like DNA, you don’t need a lot to be able to add that sample and to really all one shock the diagnostic sample.
Katherine Banwell:
Dr. Sallman, what are the essential tests that someone with AML should know about?
Dr. David Sallman:
Yeah, so, I think this is one of the keys. And I do think as many patients that could be seen at expert centers is definitely worthwhile because the challenge is the testing ability in expert centers is not just dramatically different on the speed – so, for example, we can get the mutation tests back a lot faster – but really on the comprehensive nature.
And it’s also one of those “You don’t know what you don’t know.” There’s even some testing that I’m hoping will get incorporated in our platforms within the next six to 12 months because I think there’s even some things that I may be missing from that with this. So, I would say as comprehensive as possible is the key.
Again, no matter what, people should have an evaluation of their chromosomes and a DNA-sequencing panel that incorporates all the well-described myeloid mutations. Again, these are gene sets of, let’s say, up to 100 genes on average. But again, you don’t know what you don’t know. And so, maybe tomorrow, I have a brand new therapy for mutation A. And if you’re not being tested, you won’t know. And this is already incorporating, and I could give several examples of that.